1 Johnston SC, Mendis S, Mathers CD. Global variation

in stroke burden and mor tality:estimates from

monitoring, surveillance, and modelling[J]. Lancet

Neurol, 2009, 8:345-354.

2 刘鸣, 张苏明, 饶明俐. 中国急性缺血性脑卒中诊治指

南2010[J]. 中华神经科杂志, 2010, 43:146-146.

3 Wardlaw JM, Murray V, Berge E, et al. Recombinant

tissue plasminogen activator for acute ischaemic

stroke:an updated systematic review and metaanalysis[

J]. The Lancet, 2012, 379:2364-2372.

4 Salam KA, Ummer K, Kumar P, et al. Intravenous

thrombolysis for acute ischemic stroke in the 3 to 4.5-

hour window-the Malabar experience[J]. Int J Stroke,

2013, 26:[Epub ahead of print].

5 A h me d N, Wa h l g r e n N, G r o n d M, e t a l .

Implementation and outcome of thrombolysis with

alteplase 3-4.5 h after an acute stroke:an updated

analysis from SITS-ISTR[J]. Lancet Neurol, 2010,

9:866-874.

6 Kimu r a K, Ig uch i Y, Sh iba z a k i K, e t a l. IV

t-PA therapy in acute stroke patients with atrial

fibrillation[J]. J Neurol Sci, 2009, 276:6-8.

7 Wang Y, Liao X, Zhao X, et al. Using recombinant

tissue plasminogen activator to treat acute ischemic

stroke in China analysis of the results from the

Chinese National Stroke Registry (CNSR)[J]. Stroke,

2011, 42:1658-1664.

8 Uchino K, Massaro L, Jovin TG, et al. Protocol

adherence and safety of intravenous thrombolysis

after telephone consultation with a stroke center[J]. J

Stroke Cerebrovasc Dis, 2010, 19:417-423.

9 宋红松, 黄亚文, 樊东升. 超急性期不同等级医院神经

内科卒中急诊就诊情况分析[J]. 中国医学前沿杂志(电

子版), 2012, 4:39-42.

10 张馨, 林永娟, 徐运. 缺血性卒中急性期个体化治疗的

现状和未来[J]. 中国医学前沿杂志(电子版), 2012, 4:7-

10.

11 Awadh M, MacDougall N, Santosh C, et al. Early

recurrent ischemic stroke complicating intravenous

thrombolysis for stroke incidence and association with atrial fibrillation[J]. Stroke, 2010, 41:1990-1995.

12 Saposnik G, Gladstone D, Raptis R, et al. Atrial

fibrillation in ischemic stroke predicting response to

thrombolysis and clinical outcomes[J]. Stroke, 2013,

44:99-104.

13 Zhang JB, Ding ZY, Yang Y, et al. Thrombolysis with

alteplase for acute ischemic stroke patients with atrial

fibrillation[J]. Neurol Res, 2010, 32:353-358.

14 Sanak D, Herzig R, Kral M, et al. Is atrial fibrillation

associated with poor outcome after thrombolysis?[J]. J

Neurol, 2010, 257:999-1003.

15 Seet RC, Zhang Y, Wijdicks EF, et al. Relationship

between chronic atrial fibrillation and worse outcomes

in stroke patients after intravenous thrombolysis[J].

Arch Neurol, 2011, 68:1454-1458.

16 Lou M, Sa fd a r A, Mehd i r a t t a M, e t a l. The

HAT Score:a simple grading scale for predicting

hemorrhage after thrombolysis[J]. Neurology, 2008,

71:1417-1423.

17 Mishra NK, Diener HC, Lyden PD, et al. Influence of

age on outcome from thrombolysis in acute stroke:a

controlled comparison in patients from the Virtual

International Stroke Trials Archive (VISTA)[J].

Stroke, 2010, 41:2840-2848.

18 Mazya M, Egido JA, Ford GA, et al. Predicting the

risk of symptomatic intracerebral hemorrhage in

ischemic stroke treated with intravenous alteplase

Safe Implementation of Treatments in Stroke (SITS)

symptomatic intracerebral hemorrhage risk score[J].

Stroke, 2012, 43:1524-1531.

19 Lyd e n PD. St r o k e :Ha emo r r h a g e r i s k a f t e r

thrombolysis-the SEDAN score[J]. Nat Rev Neurol,

2012, 8:246-247.

20 Frank B, Fulton R, Weimar C, et al. Impact of atrial

fibrillation on outcome in thrombolyzed patients with

stroke evidence from the Virtual International Stroke

Trials Archive (VISTA)[J]. Stroke, 2012, 43:1872-1877.

21 Sandercock P, Wardlaw JM, Lindley RI, et al. The

benefits and harms of intravenous thrombolysis with

recombinant tissue plasminogen activator within 6

h of acute ischaemic stroke (the third international

stroke trial [IST-3]):a randomised controlled trial[J].

Lancet, 2012, 379:2352-2363.

22 徐安定, 王拥军. 重组组织型纤溶酶原激活剂静脉溶

栓治疗缺血性卒中中国专家共识(2012版)[J]. 中华内

科杂志, 2012, 51:1006-1010.

23 Jauch EC, Saver JL, Adams HP, et al. Guidelines for

the early management of patients with acute ischemic

stroke:a guideline for healthcare professionals from

the American Heart Association/American Stroke

Association[J]. Stroke, 2013, 44:870-947.

24 Padjen V, Bodenant M, Jovanovic DR, et al. Outcome

of patients with atrial fibrillation after intravenous

thrombolysis for cerebral ischaemia[J]. J Neurol, 2013,

260:3049-3054.

25 Chen C, Ye M, Chen BL, et al. Thrombolysis on

ischemic stroke patients with decreased level of

consciousness within 4.5 h[J]. CNS Neurosci Ther,

2013, 19:48-52.

26 Masrur S, Abdullah AR, Smith EE, et al. Risk of

thrombolytic therapy for acute ischemic stroke

in patients with current malignancy[J]. J Stroke

Cerebrovasc Dis, 2011, 20:124-130.

27 Engelter ST, Dallongeville J, Kloss M, et al.

Thrombolysis in cervical artery dissection-data from

the Cervical Artery Dissection and Ischaemic Stroke

Patients (CADISP) database[J]. Eur J Neurol, 2012,

19:1199-1206.

28 Jin J, Guan J, Qian L, et al. Cervicocranial arterial

dissection:an analysis of the clinical features,

prognosis, and treatment efficacy[J]. Curr Neurovasc

Res, 2013, 10:157-163.

29 Engelter ST, Dallongeville J, Kloss M, et al.

Thrombolysis in cervical artery dissection-data from

the Cervical Artery Dissect[J]. Eur J Neurol, 2012,

19:1199-1206.

30 Doijiri R, Yokota C, Suzuki R, et al. Intravenous

r e c omb i n a n t t i s s u e pl a smi n o g e n a c t i v a t o r

thrombolysis in acute ischemic stroke due to middle

cerebral artery dissection[J]. J Stroke Cerebrovasc

Dis, 2012, 21, 915:e7-e9.

31 中华医学会神经病学分会脑血管病学组急性缺血性

脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治

指南2010[J]. 中华神经科杂志, 2010, 43:146-146.

32 Tanne D, Kasner SE, Demchuk AM, et al. Markers

of increased r isk of int racerebral hemor rhage

after intravenous recombinant tissue plasminogen

activator therapy for acute ischemic stroke in clinical

practice:the Multicenter rt-PA Stroke Survey[J].

Circulation, 2002, 105:1679-1685.

33 Alvarez-Sabin J, Molina CA, Montaner J, et al. Effects

of admission hyperglycemia on stroke outcome in

reperfused tissue plasminogen activator--treated

patients[J]. Stroke, 2003, 34:1235-1241.

34 Alvarez-Sabin J, Molina CA, Ribo M, et al. Impact

of admission hyperglycemia on stroke outcome after

thrombolysis:risk stratification in relation to time to

reperfusion[J]. Stroke, 2004, 35:2493-2498.

35 Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral

hemorrhage after intra-arterial thrombolysis for

ischemic stroke:the PROACT II trial[J]. Neurology,

2001, 57:1603-1610.

36 Ga rg R, Chaud hu r i A, Mu n s chaue r F, e t a l .

Hyperglycemia, insulin, and acute ischemic stroke:a

mechanistic justification for a trial of insulin infusion

therapy[J]. Stroke, 2006, 37:267-273.

37 But che r K, Ch r i st ensen S, Pa r sons M, et a l.

Post th rombolysis blood pressure elevat ion is

associated with hemorrhagic transformation[J].

Stroke, 2010, 41:72-77.

38 Tsivgou l i s G, Sa qqu r M, Sha rma VK, e t a l .

Association of pretreatment blood pressure with tissue

plasminogen activator-induced arterial recanalization

in acute ischemic stroke[J]. Stroke, 2007, 38:961-966.

39 Yong M, Kaste M. Association of characteristics of

blood pressure profiles and stroke outcomes in the

ECASS-II trial[J]. Stroke, 2008, 39:366-372.

40 Xian Y, Liang L, Smith EE, et al. Risks of intracranial

hemorrhage among patients with acute ischemic

stroke receiving warfarin and treated with intravenous

tissue plasminogen activator[J]. JAMA, 2012,

307:2600-2608.

41 Vergouwen MD, Casaubon LK, Swar tz RH, et

al. Subtherapeutic warfarin is not associated with

increased hemorrhage rates in ischemic strokes

treated with tissue plasminogen activator[J]. Stroke,

2011, 42:1041-1045.

42 Alvarez V, Rossetti AO, Papavasileiou V, et al. Acute

seizures in acute ischemic stroke:does thrombolysis

have a role to play?[J]. J Neurol, 2013, 260:55-61.

43 Ar n ol d M, St e i n l i n M, Ba uma n n A, e t a l .

Thrombolysis in childhood stroke:report of 2 cases

and review of the literature[J]. Stroke, 2009, 40:801-

807.

44 Ortiz GA, Koch S, Wallace DM, et al. Successful

intravenous thrombolysis for acute stroke in a child[J].

J Child Neurol, 2007, 22:749-752.

45 Lar rue V, von Kummer R, del Zoppo G, et al.

Hemor rhagic transformation in acute ischemic

stroke[J]. Stroke, 1997, 28:957-960.

46 Mateen FJ, Buchan AM, Hill MD. Outcomes

of th rombolysis for acute ischemic st roke in

octogenarians versus nonagenarians[J]. Stroke, 2010,

41:1833-1835.

47 Mi s h r a NK, Ahme d N, An d e r s e n G, e t a l .

Thrombolysis in very elderly people:controlled

comparison of SITS international stroke thrombolysis

registry and vir tual international stroke trials

archive[J]. BMJ, 2010, 23:341.

48 Bhatnagar P, Sinha D, Parker RA, et al. Intravenous

thrombolysis in acute ischaemic stroke:a systematic

review and meta-analysis to aid decision making in

patients over 80 years of age[J]. J Neurol Neurosurg

Psychiatry, 2011, 82:712-717.

49 Costello CA, Campbell BC, Perez de la Ossa N,

et al. Age over 80 years is not associated with

increased hemorrhagic transformation after stroke

thrombolysis[J]. J Clin Neurosci, 2012, 19:360-363.

50 山口武典, 田达郎, 峰松一夫. rt-PA (アルテプラーゼ)

静注疗法适正治疗指针[J]. 卒中, 2005, 27:327-354.

51 Yamaguchi T, Mori E, Minematsu K, et al. Alteplase

at 0.6 mg/kg for acute ischemic stroke within 3 hours

of onset Japan alteplase clinical trial (J-ACT)[J].

Stroke, 2006, 37:1810-1815.

52 Mori E, Minematsu K, Nakagawara J, et al. Effects

of 0.6 mg/kg intravenous alteplase on vascular

and clinical outcomes in middle cerebral artery

occlusion:Japan Alte-plase Clinical Trial II (J-ACT II)

[J]. Stroke, 2010, 41:461-465.

53 Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes

in mild or rapidly improving stroke not treated with

intravenous recombinant tissue-type plasminogen

activator findings from Get With The Guidelines-

Stroke[J]. Stroke, 2011, 42:3110-3115.

54 National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Recombinant tissue

plasminogen activator for minor strokes:the National

Institute of Neurological Disorders and Stroke rt-PA

Stroke Study experience[J]. Ann Emerg Med, 2005,

46:243-252.

56 Khatri P, Kleindorfer DO, Yeatts SD, et al. Strokes

with minor symptoms:an exploratory analysis of the

National Institute of Neurological Disorders and

Stroke recombinant tissue plasminogen activator

trials[J]. Stroke, 2010, 41:2581-2586.

57 Strbian D, Ringleb P, Michel P, et al. Ultra-early

intravenous stroke thrombolysis:do all patients benefit

similarly?[J]. Stroke, 2013, 44:2913-2916.

58 Menon BK, Saver JL, Prabhakaran S, et al. Risk score

for intracranial hemorrhage in patients with acute

ischemic stroke treated with intravenous tissue-type

plasminogen activator[J]. Stroke, 2012, 43:2293-2299.

59 The NINDS t-PA Stroke Study Group. Intracerebral

hemor rhage after intravenous t-PA therapy for

ischemic stroke[J]. Stroke, 1997, 28:2109-2118.

60 Whiteley WN, Slot KB, Fernandes P, et al. Risk

factors for intracranial hemorrhage in acute ischemic

stroke patients treated with recombinant tissue

plasminogen activator:a systematic review and metaanalysis

of 55 studies[J]. Stroke, 2012, 43:2904-2909.

61 Hacke W, Donnan G, Fieschi C, et al. Association of

outcome with early stroke treatment:pooled analysis

of ATLANTIS, ECASS, and NINDS rt-PA stroke

trials[J]. Lancet, 2004, 363:768-774.

62 Gonzalez RG, Furie KL, Goldmacher GV, et al. Good

outcome rate of 35% in IV-tPA-treated patients with

computed tomography angiography confirmed severe

anterior circulation occlusive stroke[J]. Stroke, 2013,

44:3109-3113.

63 Schonewille WJ, Wijman CA, Michel P, et al.

Treatment and outcomes of acute basilar artery

occlusion in the Basila r Ar ter y Inter nat ional

Cooperation Study (BASICS):a prospective registry

study[J]. Lancet Neurol, 2009, 8:724-730.

64 Lindsberg PJ, Mattle HP. Therapy of basilar artery

occlusion:a systematic analysis comparing intraarterial

and intravenous thrombolysis[J]. Stroke, 2006,

37:922-928.

65 Wardlaw JM, Murray V, Berge E, et al. Thrombolysis

for acute ischaemic stroke[J]. Cochrane Database Syst

Rev, 2009, 7:CD000213.

66 Lees KR, Bluhmki E, von Kummer R, et al. Time

to treatment with intravenous alteplase and outcome

in stroke:an updated pooled analysis of ECASS,

ATLANTIS, NINDS, and EPITHET trials[J]. Lancet,

2010, 375:1695-1703.

67 Ha cke W, Alb e r s G, Al -Rawi Y, e t a l . The

Desmoteplase in Acute Ischemic Stroke Trial (DIAS):a

phase II MRI-based 9-hour window acute stroke

thrombolysis trial with intravenous desmoteplase[J].

Stroke, 2005, 36:66-73.

68 Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous

desmoteplase in patients with acute ischaemic stroke

selected by MRI perfusion-diffusion weighted

imaging or perfusion CT (DIAS-2):a prospective,

randomised, double-blind, placebo-cont rolled

study[J]. Lancet Neurol, 2009, 8:141-150.

69 孙威, 丁则昱, 张静波. 急性脑梗死患者多模式CT

指导下的静脉溶栓治疗[J]. 中华神经科杂志, 2010,

43:256-260.